Mitochondrial metabolic reprograming via BRAF inhibition ameliorates senescence

• Published in: Experimental gerontology 2019-10, Vol.126, p.110691-110691, Article 110691
• Main Authors: Kim, Jae Won, Kuk, Myeong Uk, Choy, Hyon E., Park, Sang Chul, Park, Joon Tae
• Format: Article
• Language: English
• Subjects: BRAF; Metabolic reprogramming; Mitochondrial function; SB590885; Senescence
• ISSN: 0531-5565; 1873-6815
• DOI: 10.1016/j.exger.2019.110691

Senescence is defined as irreversible cell cycle arrest and constitutes a major driving force in diseases related to aging or premature aging. Recent studies indicate that activation of the serine/threonine protein kinase B-raf (BRAF) plays important roles in oncogene-induced senescence. However, it remains elusive whether BRAF inhibition might be effective for abrogating senescence. In this study, we assessed several BRAF inhibitors to identify compounds that ameliorate senescence and revealed SB590885 as an effective agent. Senescence-ameliorating effect upon BRAF inhibition was evident from the observation that SB590885 treatment increased cellular proliferation but diminished senescent phenotypes. Moreover, BRAF inhibition induced the mitochondrial functional recovery along with the metabolic reprogramming, which comprises two salient features that are altered in senescent cells. Furthermore, mitochondrial metabolic reprogramming via BRAF inhibition was a prerequisite for senescence amelioration. Taken together, our data revealed a novel mechanism in which senescence amelioration is mediated by mitochondrial metabolic reprogramming upon BRAF inhibition. •BRAF inhibition increased cellular proliferation but diminished senescent phenotypes.•BRAF inhibition induced the mitochondrial functional recovery along with the metabolic reprogramming.•Mitochondrial metabolic reprogramming via BRAF inhibition was a prerequisite for senescence amelioration.